Sysmex Stock Earnings Reports

Sysmex reported a significant YoY decline in Q1 FY2026 revenue and profit driven by two one-time special factors: (1) a planned global transition to a new core internal system that restricted order intake in Japan (impact: -JPY3.3 billion revenue, -JPY3.0 billion operating profit) and increased amortization; and (2) an unexpected reassessment of overseas inventory valuation (JPY1.7 billion cost of sales adjustment). Excluding these effects and currency headwinds, most regions showed local-currency growth (Americas, EMEA, AP), while Japan and China declined in Q1 (China down ~5% YoY local currency, with a 5–10% downside risk for H1 due to medical cost-containment measures). Management has revised its H1 forecast (H1 revenue cut by JPY12.5 billion to JPY240 billion; H1 operating profit cut by JPY8.5 billion to JPY36 billion) but intends to keep full-year targets intact, citing expected recovery from new product launches (XR and CN in the U.S.), progress in Alzheimer’s-related assays, medical robotics growth, expansion in emerging markets (India, Brazil, East Africa), and other mitigations (inventory, supply-chain, pricing actions vs. U.S. tariffs). Management acknowledged slower-than-expected recovery in the first half and committed to improved communication going forward.